About NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NVCR
- Previous Close: $7.70
- 50 Day Moving Average: $7.13
- 200 Day Moving Average: $7.91
- 52-Week Range: $5.95 - $18.72
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.38
- P/E Growth: -0.08
- Market Cap: $668.21M
- Outstanding Shares: 86,780,000
- Beta: 4.17
- Net Margins: -219.29%
- Return on Equity: -69.89%
- Return on Assets: -50.57%
Companies Related to NovoCure Limited:
- Debt-to-Equity Ratio: 0.61%
- Current Ratio: 9.14%
- Quick Ratio: 8.33%
What is NovoCure Limited's stock symbol?
NovoCure Limited trades on the NASDAQ under the ticker symbol "NVCR."
Where is NovoCure Limited's stock going? Where will NovoCure Limited's stock price be in 2017?
6 brokers have issued 12-month target prices for NovoCure Limited's shares. Their predictions range from $9.00 to $34.00. On average, they expect NovoCure Limited's share price to reach $18.60 in the next twelve months.
When will NovoCure Limited announce their earnings?
NovoCure Limited is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about NovoCure Limited stock?
Here are some recent quotes from research analysts about NovoCure Limited stock:
According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (1/11/2017)
J P Morgan Chase & Co analysts commented, "Novocure reported 4Q15 top-line results in-line with the commercial metrics that were pre-announced at The J.P. Morgan Healthcare Conference. Our biggest takeaway from the print and call is the ongoing progress NVCR has made thus far with Optune’s launch into newly diagnosed GBM. We had an opportunity to catch up with NVCR after the call and, while they didn’t provide guidance because of the current complexities of accounting methods, they appeared comfortable with current Street expectations. Overall, we continue to see Optune’s launch as the most crucial aspect to the NVCR story and will be closely watching its progress over the coming quarters." (3/1/2016)
Who owns NovoCure Limited stock?
NovoCure Limited's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (5.63%), State Street Corp (0.99%), Federated Investors Inc. PA (0.06%), State Board of Administration of Florida Retirement System (0.02%) and Flinton Capital Management LLC (0.02%). Company insiders that own NovoCure Limited stock include Asaf Danziger, Gert L Perlhagen, Michael J Ambrogi and Robert J Mylod Jr.
Who sold NovoCure Limited stock? Who is selling NovoCure Limited stock?
NovoCure Limited's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have sold NovoCure Limited stock in the last year include Gert L Perlhagen and Michael J Ambrogi.
Who bought NovoCure Limited stock? Who is buying NovoCure Limited stock?
NovoCure Limited's stock was acquired by a variety of institutional investors in the last quarter, including Flinton Capital Management LLC and FMR LLC. Company insiders that have bought NovoCure Limited stock in the last two years include Asaf Danziger and Robert J Mylod Jr.
How do I buy NovoCure Limited stock?
Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NovoCure Limited stock cost?
One share of NovoCure Limited stock can currently be purchased for approximately $7.70.